Thoracic Oncology Group Of Australasia (TOGA)

Conversations in Lung Cancer Research

Health EN ↓ 78 episodes

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

Be sure to visit the podcast's website and support the creator: toga-podcast.simplecast.com

Author

Thoracic Oncology Group Of Australasia (TOGA)

Category

Health

Podcast website

toga-podcast.simplecast.com

Latest episode

Oct 29, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Brain metastases in NSCLC 23.02.2023

Recent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies. In this Podcast, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Ra...

NGS panels in lung cancer 20.12.2022

In this Podcast, Dr Malinda Itchins, Medical Oncologist at Royal North Shore Hospital, Co-Chair of the Advanced Non-Small Cell Lung Cancer Group for TOGA and the Lung Cancer Chair of COSA, is joined by Professor Stephen Fox, Director of Pathology and Head of the Molecular Pathology Laboratory at the Peter MacCallum Cancer Centre in Melbourne Victoria and Professor Michael Millward, Medical Oncolog...

Lung Cancer Screening and its impact on patient care in Australia 07.12.2022

In the latest TOGA Podcast, Gavin Wright discusses Lung Cancer Screening and its impact on patient care in Australia, accessibility and practicalities of the MSAC recommendation for the lung cancer screening program. He is joined by A/Prof Emily Stone, Dept of Thoracic Medicine and Lung Transplantation, St Vincent's Hospital Sydney and A/Prof Nicole Rankin, Head, Evaluation and Implementation Scie...

The Management of Stage III NSCLC 31.10.2022

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Associate Professor Shankar Siva, Radiation Oncologist and current Cancer Council Victoria Colebatch Fellow who leads the SABR program at Peter MacCallum Cancer Centre discusses The Management of Stage III NSCLC in this podcast. Shankar is joined by Associate Professor Rachel Wong, Deputy Director of Oncology - Eastern Health, A...

The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations 12.10.2022

Welcome to the Thoracic Oncology Group of Australasia Podcast series. In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. Dr Melissa Moore Medical Oncologist from St Vincent’s Melbourne and the TOGA Education Chair, is joined by Dr Katharine See, Director a...

Cardiotoxicity and Radiation Therapy - Considerations for Lung Cancer 01.09.2022

For lung cancer patients, the benefits of treatment and potential for cure must always be balanced with risk. Cardiotoxicity is considered a short and long term risk from treatment for lung cancer, but this varies between patients. New radiotherapy techniques, lower doses of radiotherapy and supporting cardiovascular treatments can minimise the risk of cardiotoxicity. Monitoring for cardiac compli...

Accelerating Progress in Oncogene-driven Lung Cancer 09.08.2022

Deme Karikios, Medical Oncologist and Director of Clinical trials at Nepean Cancer Care Centre in Sydney is joined by Wanda Cui, Medical Oncologist from the Peter MacCallum Cancer Centre in Melbourne and Chris Karapetis,  Head of the Department of Medical Oncology and Director of Clinical Research at the Flinders Medical Centre in Adelaide. Support TOGA Thank you for listening to Conversations in...

Access to Molecular Diagnostics and Treatments Across ANZ: The Past, Present, Future 24.07.2022

The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable’ mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to i...

Practical smoking cessation advice for health care providers 30.05.2022

In this TOGA Podcast, we discuss smoking cessation in the face of smoking-related stigma and nihilism. Dr Henry Marshall, Associate Professor and Clinical Academic Fellow, UQ Thoracic Research Centre and Thoracic Physician, The Prince Charles Hospital Queensland is joined by Professor Christine Paul: Behavioural Scientist at the University of Newcastle and School of Medicine and Public Health Dr....

Consider Every Trial as a TeleTrial 30.04.2022

Barriers and facilitators and a unique insight into the patient benefits are discussed between Alexandra, patient advocate, teletrials participant and lung cancer survivor, Sabe Sabesan, medical oncologist from the ICON Cancer Centre in Townsville and co-chair of the Australian Teletrial program and the initial teletrials pilot in 2017-2020, and Craig Underhill, medical oncologist from Border Medi...

EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer 29.03.2022

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Rachel Roberts-Thomson, Medical Oncologist from Queen Elizabeth Hospital in Adelaide, discusses Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer  .  Rachel is joined byVenessa Chin from St. Vincent’s Hospital in Sydney & Angeline Low who has her own personal experience with EGFR lung cancer . EGFR mutations ar...

The need for a National Clinical Quality Registry in Lung Cancer 22.02.2022

The first TOGA Podcast for 2022 is about the need for a national clinical quality registry in lung cancer. A/Professor Emily Stone, the Deputy Chair of TOGA, is a Respiratory Physician, Senior Staff Specialist and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney. She is a conjoint Senior Lecturer at the University of New...

ALK treatment considerations in NSCLC 08.12.2021

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Mal Itchins, Medical Oncologist from Royal North Shore Hospital discusses ALK therapy choices & considerations when treating ALK NSCLC. Mal is joined by Steven Kao, Medical Oncologist from the Chris O’Brien Lifehouse and Lisa Briggs who has her own personal experience with ALK lung cancer having been diagnosed in 2014, whe...

Stigma and Nihilism In Lung Cancer : A Call to Action 23.11.2021

In this TOGA Podcast and in recognising Lung Cancer Awareness month 2021, Mel Moore, TOGA Education Chair and Medical Oncologist at St Vincent’s Hospital Melbourne, discusses the importance of treating lung cancer patients with respect, dignity and withholding the often associated judgement. The internal guilt and the pain caused by a diagnosis of lung cancer is amplified by the stigma that exists...

Challenging the Lung Cancer Stigma 08.11.2021

In this Podcast, Briony Scott discusses the stigma often associated with a diagnosis of lung cancer with Danielle and Terri – both diagnosed with lung cancer and managing the impact on their lives. They also explore self-stigma, family implications, cultural and social behaviours and systemic beliefs. Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed thi...

The Value of Comprehensive Genomic Profiling in Lung Cancer 17.10.2021

Drugs that target cancer gene mutations or rearrangements have improved outcomes for patients with many different cancers, including lung cancer, melanoma, and others . The challenge is being able to identify these genomic changes in a timely and efficient manner. Next-generation sequencing (NGS) based tumour comprehensive genomic profiling (CGP) that detects a wide range of genomic aberrations is...

Inflammation And Its Impact On The Development & Treatment Of Lung Cancer 24.09.2021

Inflammation plays an important role in pathogenesis, development and progression of lung cancer . Widespread literature exists on the prognostic impact of tumor-related factors, whereas host-related factors have not been deeply evaluated to date. Inflammatory indicators could play a vital role in assisting Medical Oncologists to identify which patients are considered at a higher probability of un...

Optimising Diagnosis & Treatment Pathways For Lung Cancer Patients 30.07.2021

Delays in diagnosis are one of the main factors associated with reduced survival rates for lung cancer patients. Clinical guidelines have been implemented in some countries to standardize the diagnosis process, better define the time from diagnosis to the beginning of treatment, and to improve clinical results in lung cancer. In Australia, periods of 14 days from the initial referral of the GP to...

Long Term Survivorship: Thriving with Metastatic Lung Cancer 24.06.2021

Welcome to the Thoracic Oncology Group of Australasia Podcast series.  This TOGA Podcast focuses on thriving with lung cancer and overcoming the challenges associated with long term survivorship and lung cancer . The past decade has seen significant advances in the management of metastatic NSCLC with the advent of multiple targeted therapies, immunotherapy approaches and combination approaches and...

Women and Lung Cancer: The Rising Tide 14.05.2021

Cigarette smoking is by far the greatest cause for lung cancer. But the proportion of lung cancer in patients who have never smoked before is on the rise.  In this podcast, Melissa Moore and Lucy Morgan discuss the increase in lung cancer diagnoses for young women who have never smoked before .  Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this epis...

Practical Perspectives: Shifting the Needle in Small Cell Lung Canceer 01.04.2021

Welcome to the Thoracic Oncology Group of Australasia Podcast series. This TOGA Podcast focuses on Small Cell Lung cancer (SCLC) – a type of lung cancer with the poorest prognosis of any lung cancer. SCLC patients make up about 13% of new lung cancer diagnoses that are characterized by early & rapid spread with only modest progress in its treatment over the last decades. Immunotherapy continues to...

Lung cancer screening works! 01.03.2021

Lung cancer screening works. Earlier detection of lung cancer presents a vastly different prognosis. Stage I disease has a median 5 year survival of greater than 65%, whereas metastatic disease has a 5 year median survival rate of 15-20%. It is time to shift the perception of a lung cancer diagnosis to that of a treatable cancer with a potential cure, through a combination of early-stage detection...

Dreaming of Better Treatments for Mesothelioma 16.02.2021

Australia has one of the highest incidence rates of mesothelioma in the world. Mesothelioma is a form of cancer that most often affects the thin linings of the organs in the chest (pleura) and abdomen (peritoneum). Mesothelioma is closely linked with asbestos exposure either at work or among family members of workers and people living in neighbourhoods near asbestos factories and mines. The risk i...

Lung Cancer Careers: Preceptorship Reflections 13.12.2020

The first virtual TOGA Preceptorship enabled 38 Preceptees involving Fellows, Advanced Trainees, Nurses and Patients to come together and discuss the landmark papers in lung cancer and the latest in treatment. A multidisciplinary group including Medical Oncology, Radiation Oncology, Respiratory, Nursing, Palliative Care and Surgery were involved and available to share expertise. Hear from two of t...

Cancer won't wait: A Cancer Australia Perspective 25.11.2020

Dorothy Keefe , CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients – a 4 week delay in diagnosis makes a difference. The red flag symptoms of lung cancer need increased education, especially for the younger, non-smoking women, who are not always aware that a lung cancer diagnosis is possible. GP awareness and early screening is also impo...

Listen to the Conversations in Lung Cancer Research podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.